z-logo
Premium
A New Approach to the Development of Disease‐Modifying Therapies for PD ; Fighting Another Pandemic
Author(s) -
Kieburtz Karl,
Katz Russell,
McGarry Andrew,
Olanow C. Warren
Publication year - 2021
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.28310
Subject(s) - disease , pandemic , medicine , covid-19 , psychological intervention , drug development , intensive care medicine , psychiatry , infectious disease (medical specialty) , drug , pathology
A disease‐modifying therapy that slows disease progression and development of disability is the major unmet need in the treatment of Parkinson's disease. Recent scientific advances suggest many promising and exciting new interventions. However, despite these opportunities, the cost, time and uncertainty of being able to receive an indication as a disease‐modifying therapy has caused many pharmaceutical companies to abandon development of potentially disease‐modifying drugs. We propose a new approach to development of these agents that will reduce the cost and facilitate approval of putative disease‐modifying drugs that should prove acceptable to pharmaceutical companies and regulatory agencies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here